| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Na Yang, Lu Lv, Shu-Meng Han, Li-Yun He, Zi-Yi Li, Yu-Cheng Yang, Fan Ping, Ling-Ling Xu, Wei Li, Hua-Bing Zhang and Yu-Xiu Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| CAMS Innovation Fund for Medical Sciences |
2023-I2M-C&T-B-043 |
| CAMS Innovation Fund for Medical Sciences |
2021-1-12M-002 |
| National High Level Hospital Clinical Research Funding |
2022-PUMCH-B-015 |
| Beijing Municipal Natural Science Foundation |
M22014 |
|
| Corresponding Author |
Hua-Bing Zhang, MD, Chief Doctor, Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing Street, Beijing 100730, China. huabingzhangchn@163.com |
| Key Words |
Insulin degludec/aspart; Type 2 diabetes management; Basal-bolus insulin therapy; Pre-mixed insulin; Diabetes treatment satisfaction questionnaire |
| Core Tip |
This study aimed to prospectively assess the efficacy, safety, and treatment satisfaction of switching from thrice-daily pre-mixed insulin or basal-bolus insulin to a twice-daily insulin degludec/aspart (IDegAsp) regimen in Chinese patients with type 2 diabetes mellitus. The results demonstrated significant improvements in fasting blood glucose levels, reduction in total insulin dosage, and enhanced patient satisfaction. These findings suggest that IDegAsp simplifies insulin therapy while maintaining effective glycemic control, thereby offering a promising alternative for optimizing diabetes management in this population. |
| Publish Date |
2024-11-30 03:48 |
| Citation |
<p>Yang N, Lv L, Han SM, He LY, Li ZY, Yang YC, Ping F, Xu LL, Li W, Zhang HB, Li YX. Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study. <i>World J Diabetes</i> 2025; 16(1): 95209</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i1/95209.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i1.95209 |
